维持轻度认知障碍患者认知功能的52周多领域干预的有效性:随机对照试验
Ha Yeong Choi1, Yeo Jin Kim2,3, Dae-Soon Son4
1Hallym University College of Medicine, Hallym University, Chuncheon, Republic of Korea.
Scientific reports
|November 20, 2025
概括
移动应用程序干预改善了轻度认知障碍 (MCI) 患者的认知功能. 这项为期52周的研究显示,干预组与对照组相比,干预组的认知评分显著提高,这表明了管理MCI的有希望的方法.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 数字健康数字健康
背景情况:
- 轻度认知障碍 (MCI) 是痴呆症的一个重要风险因素.
- 改变生活方式对于预防MCI患者认知能力下降至关重要.
- 对于MCI的移动健康干预措施的有效性需要进一步研究.
研究的目的:
- 通过使用移动应用程序评估52周的多领域干预对MCI患者认知功能的影响.
- 为了确定一个管理饮食和体育活动的移动应用程序是否可以预防认知衰退.
- 为了比较干预组和对照组之间的认知结果.
主要方法:
- 进行了一项评估者盲目的随机对照试验,80名60岁以上的参与者患有MCI和至少一个可修改的风险因素.
- 参与者被随机分配 (1:1) 到干预组 (饮食/体育活动的移动应用程序,每周≥3次) 或对照组 (一般建议,每年两次).
- 认知功能使用CERAD评估包 (MMSE-KC) 韩国版的迷你精神状态检查和修改后的波士顿命名测试进行评估.
主要成果:
- 干预组在52周后显示MMSE-KC得分明显高 (F=10.6,p<.001) 与对照组相比.
- 在干预组中,修改后的波士顿命名测试得分也明显高 (F=8.3,p<.01).
- 多领域移动应用程序干预积极影响了MCI组的认知功能变化.
结论:
- 一个多领域的移动应用程序干预显示了改善轻度认知障碍患者认知功能的潜力.
- 这种数字健康方法为管理与认知衰退相关的生活方式相关的风险因素提供了一个可行的策略.
- 进一步的研究可以探索MCI预防的移动健康干预措施的长期影响和更广泛的实施.
更多相关视频
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
1.5K
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.7K
相关概念视频
Cognitive Development During Adulthood
752
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
752
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
